Drug Trial Radar · NCT06475599
Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer
Last checked: Nov 19, 2026Latest source record: Jun 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
420
Planned (sponsor's estimate)
Start
Jul 2024
Primary completion
Dec 2027
Study completion Jun 2029
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To demonstrate that anlotinib hydrochloride capsules combined with TQB2450 injection can significantly prolong progression-free survival (PFS) compared with chemotherapy in patients with recurrent or metastatic endometrial cancer that is non- microsatellite instability high (non-MSI-H) or DNA mismatch repair deficient (non-dMMR).
Conditions
- Endometrial Cancer
Interventions
Anlotinib hydrochloride capsule + TQB2450 injectionDrug
Anlotinib hydrochloride capsule is a multi-target tyrosine kinase inhibitor, which targets VEGFR (VEGFR-1, VEGFR-2 and VEGFR-3), PDGFR, FGFR and c-Kit, etc. It can inhibit tumor progression by inhibiting angiogenesis and tumor growth at the same time. TQB2450 injection is a humanized monoclonal antibody targeting programmed death ligand 1 (PD-L1) that prevents the binding of PD-L1 to the PD-1 and B7.1 receptors on the T-cell surface, allowing T-cell reactivation and thus enhancing the immune response.
Chemotherapy drugDrug
Based on each patient's condition and previous treatment history, the investigator will select one of the chemotherapy drugs (including Paclitaxel, Albumin, Doxorubicin and Doxorubicin hydrochloride) for treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS) assessed by independent imaging review committee (IRC)Time frame: Up to 36 months after study start
Locations
61 sites in 1 country. Site status is shown where the registry gives one.
Beijing Obstetrics and Gynecology Hospital, Capital Medical University
Beijing, China
Beijing Chaoyang Hospital, Capital Medical University
Beijing, China
Chongqing University Cancer Hospital
Chongqing, China
The Southwest Hospital of Amu
Chongqing, China
Chongqing University Three Gorges Hospital
Chongqing, China
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, China
The Affiliated Hospital of Southwest Medical University
Chongqing, China
Fudan University Shanghai Cancer Center
Shanghai, China
Shanghai Tenth People's Hospital
Shanghai, China
Obstetrics & Gynecology Hospital of Fudan University
Shanghai, China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China
Tianjin Central Hospital of Gynecology Obstetrics
Tianjin, China
Anhui Provincial Hospital
Hefei, Anhui, China
Fujian Cancer Hospital
Fuzhou, Fujian, China
First Hospital of Lanzhou University
Lanzhou, Gansu, China
Gansu Provincial Cancer Hospital
Lanzhou, Gansu, China
Sun Yat-sen Memorial Hospital
Guangzhou, Guangdong, China
The First Affiliated Hospital of Jinan University
Guangzhou, Guangdong, China
Huizhou Central People's Hospital
Huizhou, Guangdong, China
Jiangmen Central Hospital
Jiangmen, Guangdong, China
Meizhou People's Hospital
Meizhou, Guangdong, China
Guigang City People's Hospital
Guigang, Guangxi, China
Nanxishan Hospital of Guangxi Zhuang Autonomous Region
Guilin, Guangxi, China
Liuzhou People's Hospital
Liuzhou, Guangxi, China
Liuzhou Municipal Liutie Central Hospital
Liuzhou, Guangxi, China
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China
Hainan Ceneral Hospital
Haikou, Hainan, China
Tangshan People's Hospital
Tangshan, Hebei, China
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China
Nanyang first People's Hospital National Third Class A Hospital
Nanyang, Henan, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Hubei Cancer Hospital
Wuhan, Hubei, China
Hunan Cancer Hospital
Changsha, Hunan, China
The Central Hospital Of Shaoyang
Shaoyang, Hunan, China
Inner Mongolia Autonomous Region People's Hospital
Hohhot, Inner Mongolia, China
Changchun Tumor Hospital
Changchun, Jilin, China
The first hospital of Jilin University
Changchun, Jilin, China
Liaoning Cancer Hospital
Shenyang, Liaoning, China
Shengjing Hospital Of China Medical University
Shenyang, Liaoning, China
Showing 40 of 61 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.